公开(公告)号：US09452986B2

公开(公告)日：2016-09-27

申请号：US14613579

申请日：2015-02-04

申请人： AbbVie Inc.

发明人： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC分类号： C07D215/48 ,  C07D401/12 ,  C07D409/14 ,  C07D487/08 ,  C07D401/14 ,  C07D487/04 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12

CPC分类号： C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

摘要： Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20190119200A1

公开(公告)日：2019-04-25

申请号：US16091919

申请日：2017-04-06

申请人： AbbVie Inc.

发明人： Lawrence A. Black ,  William H. Bunnelle ,  Da Chen ,  Bruce Clapham ,  David A. Degoey ,  Xiangjun Deng ,  Liqiang Fu ,  Lisa A. Hazelwood ,  Linglong Kong ,  Qingyu Lang ,  Chih-Hung Lee ,  Mingfeng Li ,  Greta L. Lundgaard ,  Meena V. Patel ,  Ruihong Tao ,  Lin Zhang ,  Qingwei Zhang ,  Qiangang Zheng ,  Wei Zhu

IPC分类号： C07C235/34 ,  C07D213/69 ,  C07D321/10 ,  C07D307/86 ,  C07D317/46 ,  C07D333/24 ,  C07C323/52 ,  C07F9/38 ,  C07C313/04 ,  C07D209/20 ,  C07C311/32 ,  C07D305/06 ,  C07D213/71 ,  C07C311/51 ,  C07D239/72 ,  C07D239/52 ,  C07D257/06 ,  C07D215/50 ,  C07D217/26 ,  C07D498/04 ,  C07D307/33

摘要： Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation of lysophosphatidic acid receptor 1. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US09969693B2

公开(公告)日：2018-05-15

申请号：US15239554

申请日：2016-08-17

申请人： AbbVie Inc.

发明人： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC分类号： C07D215/48 ,  C07D401/12 ,  C07D409/14 ,  C07D487/08 ,  C07D401/14 ,  C07D487/04 ,  C07D405/14 ,  C07D417/14 ,  C07D471/04

CPC分类号： C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

摘要： Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav 1.7 and/or Nav 1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20150218102A1

公开(公告)日：2015-08-06

申请号：US14613579

申请日：2015-02-04

申请人： AbbVie Inc.

发明人： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC分类号： C07D215/48 ,  C07D409/14 ,  C07D487/08 ,  C07D471/04 ,  C07D487/04 ,  C07D405/14 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14

CPC分类号： C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

摘要： Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

摘要翻译： 式（I）化合物及其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，R2和R3如本说明书中所定义，可用于治疗由电压门控钠预防或改善的病症或病症 通道，例如Nav1.7和/或Nav1.8。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。

公开(公告)号：US20160355482A1

公开(公告)日：2016-12-08

申请号：US15239554

申请日：2016-08-17

申请人： AbbVie Inc.

发明人： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC分类号： C07D215/48 ,  C07D409/14 ,  C07D487/08 ,  C07D471/04 ,  C07D487/04 ,  C07D405/14 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14

CPC分类号： C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

摘要： Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

摘要翻译： 和其药学上可接受的盐，酯，酰胺或放射性标记形式，其中R1，R2和R3如说明书中所定义，可用于治疗由电压门控钠通道（例如Nav1）预防或改善的病症或病症。 7和/或Nav1.8。 公开了制备化合物的方法。 还公开了式（I）化合物的药物组合物，以及使用这些化合物和组合物的方法。

公开(公告)号：US20180334435A1

公开(公告)日：2018-11-22

申请号：US15952682

申请日：2018-04-13

申请人： AbbVie Inc.

发明人： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC分类号： C07D215/48 ,  C07D487/04 ,  C07D405/12 ,  C07D487/08 ,  C07D401/12 ,  C07D471/04 ,  C07D417/14 ,  C07D405/14 ,  C07D409/14 ,  C07D401/14 ,  C07D409/12 ,  C07D417/12

CPC分类号： C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

摘要： Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20170226062A9

公开(公告)日：2017-08-10

申请号：US15239554

申请日：2016-08-17

申请人： AbbVie Inc.

发明人： Andrew Bogdan ,  Marlon D. Cowart ,  David A. DeGoey ,  Tammie K. Jinkerson ,  John R. Koenig ,  Michael E. Kort ,  Bo Liu ,  Mark A. Matulenko ,  Derek W. Nelson ,  Meena V. Patel ,  Hillary Peltier ,  Marc J. Scanio ,  Brian D. Wakefield

IPC分类号： C07D215/48 ,  C07D409/14 ,  C07D487/08 ,  C07D471/04 ,  C07D487/04 ,  C07D405/14 ,  C07D417/14 ,  C07D401/12 ,  C07D401/14

CPC分类号： C07D215/48 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08

摘要： Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, R2, and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Nav1.7 and/or Nav1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

公开(公告)号：US20150231141A1

公开(公告)日：2015-08-20

申请号：US14628131

申请日：2015-02-20

申请人： AbbVie Inc.

发明人： Alan S. Florjancic ,  Michael J. Dart ,  Keith B. Ryther ,  Arturo Perez-Medrano ,  William A. Carroll ,  Meena V. Patel ,  Karin Rosemarie Tietje ,  Tongmei Li ,  Teodozyj Kolasa ,  Megan E. Gallagher ,  Sridhar Peddi ,  Jennifer M. Frost ,  Derek W. Nelson

IPC分类号： A61K31/5377 ,  A61K31/4439 ,  A61K31/428 ,  A61K31/427 ,  A61K31/506 ,  A61K31/426 ,  A61K31/4709

CPC分类号： A61K31/429 ,  C07D277/46 ,  C07D277/48 ,  C07D277/82 ,  C07D417/04 ,  C07D417/06 ,  C07D417/12 ,  C07D493/08 ,  C07D513/04

摘要： The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L2, are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

摘要翻译： 本发明涉及式（I）化合物或其药学上可接受的盐，前药，前体药物或其组合的盐，其中R1，R2，R3，R4和L2在说明书中定义，包含这些化合物的组合物， 以及使用这些化合物和组合物治疗病症和病症的方法。